Literature DB >> 24057326

The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features.

Matthew D Cykowski1, Richard A Allen, Angela C Kanaly, Kar-Ming Fung, Roxanne Marshall, Arie Perry, Ethan D Stolzenberg, S Terence Dunn.   

Abstract

Rare pilocytic astrocytomas (PA) have atypical histologic and clinicoradiologic features that raise the differential diagnosis of glioblastoma. Whether ancillary studies can supplement histopathologic examination in placing these cases accurately on the spectrum of WHO Grade I PA to higher-grade glioma is not always clear, partly because these cases are not common. Here, ten PAs with atypical clinicoradiologic and histologic features and six pediatric glioblastoma multiforme (pGBMs) were analyzed for BRAF V600E, IDH1, IDH2, and TP53 mutations. Ki-67, p53, and p16 protein expression were also examined by immunohistochemistry. BRAF-KIAA1549 fusion status was assessed in the PA subgroup. The rate of BRAF-KIAA1549 fusion was high in these PAs (5/7 tumors) including four extracerebellar examples. A single BRAF V600E mutation was identified in the fusion-negative extracerebellar PA of a very young child who succumbed to the disease. TP53 mutations were present only in malignant gliomas, including three pGBMs and one case designated as PA with anaplastic features (with consultation opinion of pGBM). IDH1 and IDH2 were wild type in all cases, consistent with earlier findings that IDH mutations are not typical in high-grade gliomas of patients ≤14 years of age. Immunohistochemical studies showed substantial overlap in Ki-67 labeling indices, an imperfect correlation between p53 labeling and TP53 mutation status, and complete p16 loss in only two pGBMs but in no PAs. These results suggest that (a) BRAF-KIAA1549 fusion may be common in PAs with atypical clinicoradiologic and histologic features, including those at extracerebellar sites, (b) BRAF V600E mutation is uncommon in extracerebellar PAs, and (c) TP53 mutation analysis remains a valuable tool in identifying childhood gliomas that will likely behave in a malignant fashion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24057326     DOI: 10.1007/s11060-013-1249-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  28 in total

1.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.

Authors:  Genevieve Schindler; David Capper; Jochen Meyer; Wibke Janzarik; Heymut Omran; Christel Herold-Mende; Kirsten Schmieder; Pieter Wesseling; Christian Mawrin; Martin Hasselblatt; David N Louis; Andrey Korshunov; Stefan Pfister; Christian Hartmann; Werner Paulus; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2011-01-29       Impact factor: 17.088

2.  Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.

Authors:  Yongji Tian; Benjamin E Rich; Natalie Vena; Justin M Craig; Laura E Macconaill; Veena Rajaram; Stewart Goldman; Hala Taha; Madeha Mahmoud; Memet Ozek; Aydin Sav; Janina A Longtine; Neal I Lindeman; Levi A Garraway; Azra H Ligon; Charles D Stiles; Sandro Santagata; Jennifer A Chan; Mark W Kieran; Keith L Ligon
Journal:  J Mol Diagn       Date:  2011-08-30       Impact factor: 5.568

3.  Genotype-phenotype correlation in gemistocytic astrocytomas.

Authors:  S Kösel; B W Scheithauer; M B Graeber
Journal:  Neurosurgery       Date:  2001-01       Impact factor: 4.654

4.  High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors.

Authors:  V M Hayes; C M Dirven; A Dam; E Verlind; W M Molenaar; J J Mooij; R M Hofstra; C H Buys
Journal:  Brain Pathol       Date:  1999-07       Impact factor: 6.508

5.  p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas.

Authors:  S Patt; H Gries; M Giraldo; J Cervos-Navarro; H Martin; W Jänisch; J Brockmöller
Journal:  Hum Pathol       Date:  1996-06       Impact factor: 3.466

6.  Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.

Authors:  Craig Horbinski; Marina N Nikiforova; Jill M Hagenkord; Ronald L Hamilton; Ian F Pollack
Journal:  Neuro Oncol       Date:  2012-04-05       Impact factor: 12.300

7.  The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma.

Authors:  Adrian J Frank; Roberto Hernan; Andrew Hollander; Janet C Lindsey; Meryl E Lusher; Christine E Fuller; Steven C Clifford; Richard J Gilbertson
Journal:  Brain Res Mol Brain Res       Date:  2004-02-05

8.  Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.

Authors:  Andrey Korshunov; Jochen Meyer; David Capper; Arne Christians; Marc Remke; Hendrik Witt; Stefan Pfister; Andreas von Deimling; Christian Hartmann
Journal:  Acta Neuropathol       Date:  2009-06-19       Impact factor: 17.088

9.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.

Authors:  Simon A Forbes; Nidhi Bindal; Sally Bamford; Charlotte Cole; Chai Yin Kok; David Beare; Mingming Jia; Rebecca Shepherd; Kenric Leung; Andrew Menzies; Jon W Teague; Peter J Campbell; Michael R Stratton; P Andrew Futreal
Journal:  Nucleic Acids Res       Date:  2010-10-15       Impact factor: 16.971

10.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Authors:  David T W Jones; Sylvia Kocialkowski; Lu Liu; Danita M Pearson; L Magnus Bäcklund; Koichi Ichimura; V Peter Collins
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more
  6 in total

1.  Differentiation between pilocytic astrocytoma and glioblastoma: a decision tree model using contrast-enhanced magnetic resonance imaging-derived quantitative radiomic features.

Authors:  Fei Dong; Qian Li; Duo Xu; Wenji Xiu; Qiang Zeng; Xiuliang Zhu; Fangfang Xu; Biao Jiang; Minming Zhang
Journal:  Eur Radiol       Date:  2018-11-12       Impact factor: 5.315

2.  A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas.

Authors:  David Bret; Valentin Chappuis; Delphine Poncet; François Ducray; Karen Silva; Fabrice Mion; Alexandre Vasiljevic; Carole Ferraro-Peyret; Carmine Mottolese; Pierre Leblond; Mathieu Gabut; Didier Frappaz; Nathalie Streichenberger; David Meyronet; Pierre-Paul Bringuier; Marc Barritault
Journal:  Mol Diagn Ther       Date:  2019-08       Impact factor: 4.074

3.  p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.

Authors:  Roberta Soares Faccion; Paula Sabbo Bernardo; Giselle Pinto Faria de Lopes; Leonardo Soares Bastos; Cristina Lordello Teixeira; José Antonio de Oliveira; Priscila Valverde Fernandes; Luiz Gustavo Dubois; Leila Chimelli; Raquel Ciuvalschi Maia
Journal:  Cell Oncol (Dordr)       Date:  2018-01-26       Impact factor: 6.730

Review 4.  Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.

Authors:  Catherine Louise Penman; Claire Faulkner; Stephen P Lowis; Kathreena M Kurian
Journal:  Front Oncol       Date:  2015-03-03       Impact factor: 6.244

5.  mTOR activation is increased in pilocytic astrocytomas from older adults compared with children.

Authors:  Mahlon D Johnson; Mary O'Connell; Kevin Walter; Howard Silberstein
Journal:  Surg Neurol Int       Date:  2017-05-26

6.  Adult pilocytic astrocytoma in the molecular era: a comprehensive review.

Authors:  Timothy A Gregory; Lyndon B Chumbley; John W Henson; Brett J Theeler
Journal:  CNS Oncol       Date:  2021-01-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.